HK1044337B - 酰胺化合物 - Google Patents

酰胺化合物 Download PDF

Info

Publication number
HK1044337B
HK1044337B HK02105923.9A HK02105923A HK1044337B HK 1044337 B HK1044337 B HK 1044337B HK 02105923 A HK02105923 A HK 02105923A HK 1044337 B HK1044337 B HK 1044337B
Authority
HK
Hong Kong
Prior art keywords
group
compound
formula
salt
substituted
Prior art date
Application number
HK02105923.9A
Other languages
English (en)
Chinese (zh)
Other versions
HK1044337A1 (en
Inventor
山田明
青木敏
Original Assignee
安斯泰来制药有限公司
安斯泰來制藥有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 安斯泰来制药有限公司, 安斯泰來制藥有限公司 filed Critical 安斯泰来制药有限公司
Publication of HK1044337A1 publication Critical patent/HK1044337A1/xx
Publication of HK1044337B publication Critical patent/HK1044337B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK02105923.9A 1999-01-14 2000-01-06 酰胺化合物 HK1044337B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPP8180A AUPP818099A0 (en) 1999-01-14 1999-01-14 New n-containing heterocyclic compounds
AUPP8180 1999-01-14
PCT/JP2000/000017 WO2000042011A1 (en) 1999-01-14 2000-01-06 Amide compounds

Publications (2)

Publication Number Publication Date
HK1044337A1 HK1044337A1 (en) 2002-10-18
HK1044337B true HK1044337B (zh) 2004-11-26

Family

ID=3812385

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02105923.9A HK1044337B (zh) 1999-01-14 2000-01-06 酰胺化合物

Country Status (21)

Country Link
US (2) US6710043B1 (https=)
EP (1) EP1140836B1 (https=)
JP (2) JP3617454B2 (https=)
KR (2) KR100525809B1 (https=)
CN (1) CN1142910C (https=)
AR (1) AR028812A1 (https=)
AT (1) ATE502923T1 (https=)
AU (1) AUPP818099A0 (https=)
BR (1) BRPI0008753B8 (https=)
CA (1) CA2360360C (https=)
CZ (1) CZ20012562A3 (https=)
DE (1) DE60045759D1 (https=)
ES (1) ES2363492T3 (https=)
HK (1) HK1044337B (https=)
HU (1) HU230422B1 (https=)
IL (2) IL143841A0 (https=)
RU (1) RU2208608C2 (https=)
TR (1) TR200102038T2 (https=)
TW (1) TWI229075B (https=)
WO (1) WO2000042011A1 (https=)
ZA (1) ZA200104713B (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6344358B1 (en) * 1999-05-28 2002-02-05 Fujisawa Pharmaceutical Co., Ltd. Agent for expression of long-term potentiation of synaptic transmission comprising compound having brain somatostatin activation property
UY27003A1 (es) 2000-11-06 2002-07-31 Schering Ag Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer
CA2431181A1 (en) * 2000-12-07 2002-06-13 Nobuya Matsuoka Nootropic effect enhancer
AU2002360561A1 (en) * 2001-12-11 2003-06-23 Sepracor, Inc. 4-substituted piperidines, and methods of use thereof
WO2004052102A1 (en) * 2002-12-06 2004-06-24 Dow Agrosciences Llc Synergistic compositions
CA2520763A1 (en) 2003-04-03 2004-10-21 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
EP1765311A4 (en) 2004-03-16 2009-04-29 Univ California REDUCTION OF NEPHROPATHY WITH INHIBITORS OF SOLUBLE EPOXY HYDROLASE AND EPOXYEICOSANOIDS
TW200630337A (en) 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
US7662910B2 (en) 2004-10-20 2010-02-16 The Regents Of The University Of California Inhibitors for the soluble epoxide hydrolase
CA2579227A1 (en) * 2004-11-04 2006-05-18 Neurogen Corporation Arylalkyl ureas as cb1 antagonists
WO2007031791A1 (en) 2005-09-16 2007-03-22 Arrow Therapeutics Limited Biphenyl derivatives and their use in treating hepatitis c
AR059826A1 (es) * 2006-03-13 2008-04-30 Univ California Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble
WO2007110449A1 (en) 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
TW200815353A (en) 2006-04-13 2008-04-01 Euro Celtique Sa Benzenesulfonamide compounds and their use
US8937181B2 (en) 2006-04-13 2015-01-20 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
CA2666482A1 (en) * 2006-10-20 2008-05-02 Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors
US20080200444A1 (en) * 2006-10-20 2008-08-21 Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors
GB0706793D0 (en) * 2007-04-05 2007-05-16 Evotec Ag Compounds
US8399486B2 (en) 2007-04-09 2013-03-19 Purdue Pharma L.P. Benzenesulfonyl compounds and the use thereof
CN101687795B (zh) 2007-04-20 2013-05-08 千寿制药株式会社 轴突形成促进剂
US8765736B2 (en) 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
EP2463282B1 (en) 2007-11-05 2013-08-07 Novartis AG 4-Benzylamino-1-carboxyacyl-piperidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis
MX2010006063A (es) 2007-12-03 2010-07-01 Novartis Ag Derivados de 4-bencil-amino-pirrolidina 1,2-disustituida como inhibidores de la proteina de transferencia de colesteril-ester (cetp) utiles para el tratamiento de las enfermedades tales como hiperlipidemia o arterioesclerosis.
GB0813142D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
GB0813144D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
WO2011060321A1 (en) 2009-11-16 2011-05-19 Chdi, Inc. Transglutaminase tg2 inhibitors, pharmaceutical compositions, and methods of use thereof
EP2528604B1 (en) 2010-01-29 2017-11-22 The Regents of the University of California Acyl piperidine inhibitors of soluble epoxide hydrolase
US8889716B2 (en) 2011-05-10 2014-11-18 Chdi Foundation, Inc. Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4939679B1 (https=) * 1969-06-30 1974-10-28
US3647805A (en) 1969-07-11 1972-03-07 Kyorin Seiyaku Kk Benzoylamino substituted 1-benzoyl-piperidines
BE791501A (fr) * 1971-11-19 1973-05-17 Albert Ag Chem Werke Diamines cycliques n,n'-disubstituees et leur procede de preparation
GB1416872A (en) * 1972-03-10 1975-12-10 Wyeth John & Brother Ltd 4-aminoquinoline derivatives
JPS5152176A (https=) * 1974-10-12 1976-05-08 Yoshitomi Pharmaceutical
DE2860314D1 (en) * 1977-11-24 1981-02-19 Synthelabo Derivatives of naphthalene, process for their preparation and their therapeutic application
DE3544244A1 (de) * 1985-12-14 1987-06-25 Minnesota Mining & Mfg Vorrichtung zum entnehmen von fuellgut aus beuteln
DE3784401T2 (de) 1986-07-31 1993-08-12 Otsuka Pharma Co Ltd Karbostyril-derivate und ihre salze, verfahren zu ihrer herstellung und diese enthaltende kardiotonische zusammensetzung.
CA1322199C (en) * 1987-07-15 1993-09-14 Masami Eigyo N-¬(2-oxopyrrolidin-1-yl) acetyl)| piperazine derivatives and drug for senile dementia
JPH0696575B2 (ja) 1987-09-17 1994-11-30 三菱化成株式会社 ４−アミノピリジン誘導体及びその酸付加塩
US5346907A (en) * 1988-04-05 1994-09-13 Abbott Laboratories Amino acid analog CCK antagonists
GB8917687D0 (en) * 1989-08-02 1989-09-20 Fujisawa Pharmaceutical Co Aminopiperazine derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
RU2024507C1 (ru) * 1991-11-18 1994-12-15 Евгений Яковлевич Левитин 5-хлор-2-пиридиламид-4-нитро-n-(карбоксиметил)антраниловой кислоты, проявляющий противовоспалительную активность
CA2077252C (en) * 1992-08-31 2001-04-10 Khashayar Karimian Methods of making ureas and guanidines, and intermediates therefor
US5723490A (en) 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
ATE219766T1 (de) 1993-04-07 2002-07-15 Otsuka Pharma Co Ltd N-acylierte 4-aminopiperidin derivate als aktive bestandteile von peripher gefässerweiternden wikstoffen
CA2123728A1 (en) * 1993-05-21 1994-11-22 Noriyoshi Sueda Urea derivatives and their use as acat inhibitors
DE4319038A1 (de) * 1993-06-08 1994-12-15 Bayer Ag Verwendung von teilweise bekannten substituierten Chromanen als Arzneimittel, neue Wirkstoffe und Verfahren zu ihrer Herstellung
PT704439E (pt) * 1993-06-18 2001-12-28 Fujisawa Pharmaceutical Co Novo intermediario para utilizacao sintetica e processo para a preparacao de derivados de aminopiperazina
US5500423A (en) * 1994-09-09 1996-03-19 Hoechst-Roussel Pharmaceuticals Inc. 5,6-dihydro-4H-imidazo[4,5,1-ij]quinolines
MX9707561A (es) 1995-04-07 1997-12-31 Schering Corp Compuestos de carbonil piperazinilo y piperidinilo.
GB9519077D0 (en) * 1995-09-18 1995-11-15 Fujisawa Pharmaceutical Co New heterocyclic compounds
US6077857A (en) * 1995-11-13 2000-06-20 Smithkline Beecham Corporation Hemoregulatory compounds
FR2744449B1 (fr) 1996-02-02 1998-04-24 Pf Medicament Nouvelles piperazines aromatiques derivees de cycloazanes substitues, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments
ZA9710872B (en) * 1996-12-12 1998-06-15 Fujisawa Pharmaceutical Co N-(4-acetyl-1-piperazinyl)-4-fluorobenzamide hydrate.
JP2001506580A (ja) * 1996-12-24 2001-05-22 藤沢薬品工業株式会社 アミノピペラジン誘導体の新規用途
EP0968201A2 (en) 1997-02-17 2000-01-05 Fujisawa Pharmaceutical Co., Ltd. New aminopiperazine derivatives
US6344358B1 (en) * 1999-05-28 2002-02-05 Fujisawa Pharmaceutical Co., Ltd. Agent for expression of long-term potentiation of synaptic transmission comprising compound having brain somatostatin activation property

Also Published As

Publication number Publication date
AR028812A1 (es) 2003-05-28
BRPI0008753B8 (pt) 2021-05-25
JP2004002414A (ja) 2004-01-08
CA2360360C (en) 2009-09-08
IL143841A (en) 2006-07-05
KR100520406B1 (ko) 2005-10-11
HUP0105108A3 (en) 2002-11-28
WO2000042011A1 (en) 2000-07-20
AUPP818099A0 (en) 1999-02-11
JP3617454B2 (ja) 2005-02-02
CN1142910C (zh) 2004-03-24
CA2360360A1 (en) 2000-07-20
US20040014745A1 (en) 2004-01-22
TR200102038T2 (tr) 2002-01-21
ATE502923T1 (de) 2011-04-15
EP1140836B1 (en) 2011-03-23
KR20010093819A (ko) 2001-10-29
KR20040063001A (ko) 2004-07-09
HUP0105108A2 (hu) 2002-05-29
EP1140836A1 (en) 2001-10-10
US6710043B1 (en) 2004-03-23
HK1044337A1 (en) 2002-10-18
DE60045759D1 (de) 2011-05-05
KR100525809B1 (ko) 2005-11-03
ZA200104713B (en) 2002-09-09
TWI229075B (en) 2005-03-11
CN1336917A (zh) 2002-02-20
JP2002534503A (ja) 2002-10-15
CZ20012562A3 (cs) 2001-11-14
HU230422B1 (hu) 2016-05-30
RU2208608C2 (ru) 2003-07-20
BR0008753B1 (pt) 2013-11-12
ES2363492T3 (es) 2011-08-05
IL143841A0 (en) 2002-04-21
BR0008753A (pt) 2001-11-06

Similar Documents

Publication Publication Date Title
HK1044337A1 (en) Amide compounds
CN1038839C (zh) 一类环胺化合物的制备方法
CN1243751C (zh) 用作抗变态反应药物的哌啶化合物
CN1118452C (zh) 1－[(1－取代－4－哌啶基)甲基]－4－哌啶衍生物、其生产方法、含有该化合物的药物组合物和这些化合物的中间体
CN1298715C (zh) 作为组胺h3拮抗剂的非咪唑化合物
CN1780621A (zh) 作为γ分泌酶抑制剂的磺酰胺衍生物
CN1229373C (zh) 作为神经激肽1拮抗剂的哌啶衍生物
CN1678317A (zh) 用作治疗呕吐、抑郁症、焦虑症和咳嗽的神经激肽－1(nk－1)拮抗剂的1－酰氨基－4－苯基－4－苄氧基甲基－哌啶衍生物和相关化合物
CN1226888A (zh) 含氟－1,4－二取代哌啶衍生物
CN1239952A (zh) 用作nos抑制剂的6－苯基吡啶基－2－胺衍生物
CN1662524A (zh) 用作组胺h3拮抗剂的吲哚衍生物
CN1585749A (zh) 类大麻苷受体配体
CN1658875A (zh) 用作组胺h3拮抗剂的1－(4－哌啶基)苯并咪唑酮
CN1290251A (zh) N－酰基环胺衍生物
CN1946402A (zh) 用作ccr3拮抗剂的哌啶衍生物
CN1812980A (zh) 哌啶基－和哌嗪基－烷基氨基甲酸酯衍生物,其制备及治疗用途
CN1617869A (zh) 作为尿压素ⅱ受体拮抗剂的4－(哌啶基－吡咯烷基－烷基－脲基)－喹啉类化合物
CN1787818A (zh) 趋化因子受体活性的氨基环丁基酰胺调节剂
CN1744930A (zh) 治疗雄激素依赖性疾病的3型17β－羟基类固醇脱氢酶抑制剂
CN1032438A (zh) 新的取代的n-(1-烷基-3-羟基-4-哌啶基)苯甲酰胺
CN1114591C (zh) 环酰胺化合物
CN1097192A (zh) 逆转录酶病毒蛋白酶抑制剂
CN101048393A (zh) 作为γ－分泌酶抑制剂的取代的N－芳基磺酰基杂环胺
CN101080392A (zh) 作为抗肥胖药剂的哌嗪基吡啶衍生物
CN1124026A (zh) 新型哌啶基硫代吲哚衍生物，它们的制备方法，和含有它们的药物组合物，作为止痛药的用途

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170106